全文获取类型
收费全文 | 155475篇 |
免费 | 11165篇 |
国内免费 | 617篇 |
专业分类
耳鼻咽喉 | 1762篇 |
儿科学 | 3859篇 |
妇产科学 | 2606篇 |
基础医学 | 20440篇 |
口腔科学 | 3382篇 |
临床医学 | 15286篇 |
内科学 | 32637篇 |
皮肤病学 | 3240篇 |
神经病学 | 14416篇 |
特种医学 | 6931篇 |
外国民族医学 | 14篇 |
外科学 | 25034篇 |
综合类 | 1937篇 |
一般理论 | 109篇 |
预防医学 | 11502篇 |
眼科学 | 3273篇 |
药学 | 10069篇 |
中国医学 | 235篇 |
肿瘤学 | 10525篇 |
出版年
2023年 | 805篇 |
2022年 | 586篇 |
2021年 | 2949篇 |
2020年 | 2079篇 |
2019年 | 3118篇 |
2018年 | 3592篇 |
2017年 | 2797篇 |
2016年 | 3135篇 |
2015年 | 3584篇 |
2014年 | 5090篇 |
2013年 | 6847篇 |
2012年 | 10339篇 |
2011年 | 11003篇 |
2010年 | 6308篇 |
2009年 | 6013篇 |
2008年 | 9753篇 |
2007年 | 10188篇 |
2006年 | 10085篇 |
2005年 | 10127篇 |
2004年 | 9299篇 |
2003年 | 8593篇 |
2002年 | 8243篇 |
2001年 | 2125篇 |
2000年 | 1785篇 |
1999年 | 2002篇 |
1998年 | 1655篇 |
1997年 | 1290篇 |
1996年 | 1075篇 |
1995年 | 1215篇 |
1994年 | 1103篇 |
1993年 | 990篇 |
1992年 | 1265篇 |
1991年 | 1186篇 |
1990年 | 1023篇 |
1989年 | 969篇 |
1988年 | 898篇 |
1987年 | 876篇 |
1986年 | 875篇 |
1985年 | 856篇 |
1984年 | 907篇 |
1983年 | 781篇 |
1982年 | 937篇 |
1981年 | 836篇 |
1980年 | 719篇 |
1979年 | 646篇 |
1978年 | 643篇 |
1977年 | 516篇 |
1976年 | 490篇 |
1974年 | 504篇 |
1973年 | 439篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Espersen Caroline Modin Daniel Hoffmann Søren Hagemann Christoffer A. Hagemann Rikke A. Olsen Flemming J. Fritz-Hansen Thomas Platz Elke Møgelvang Rasmus Biering-Sørensen Tor 《The international journal of cardiovascular imaging》2022,38(1):131-140
The International Journal of Cardiovascular Imaging - Global longitudinal strain (GLS) has proven to be a powerful prognostic marker in various patient populations, but the prognostic value of... 相似文献
2.
Avarave Steffi Thomas Jibu 《Proceedings of the National Academy of Sciences, India. Section B.》2022,92(2):329-340
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences - Exploration on DNA-based investigations is frequently obscured by being constrained to work in suboptimal... 相似文献
3.
4.
Die Anaesthesiologie - Simulationstraining ist für die Notfallmedizin unverzichtbar, insbesondere in Hinsicht auf eine verbesserte Patientensicherheit. Methoden und Technologien umfassen ein... 相似文献
5.
Die Anaesthesiologie - 相似文献
6.
Tobias Hüppe Sascha Kreuer Hinnerk Wulf Dennik Freitag Martin Seidel Tobias Teucke Felix Maurer Andreas Kirschbaum Tilo Koch Frank Langer Thomas Volk Carsten Feldmann 《Acta anaesthesiologica Scandinavica》2023,67(4):455-461
Background
Volatile propofol can be measured in exhaled air and correlates to plasma concentrations with a time delay. However, the effect of single-lung ventilation on exhaled propofol is unclear. Therefore, our goal was to evaluate exhaled propofol concentrations during single-lung compared to double-lung ventilation using double-lumen tubes.Methods
In a first step, we quantified adhesion of volatile propofol to the inner surface of double-lumen tubes during double- and single-lumen ventilation in vitro. In a second step, we enrolled 30 patients scheduled for lung surgery in two study centers. Anesthesia was provided with propofol and remifentanil. We utilized left-sided double-lumen tubes to separately ventilate each lung. Exhaled propofol concentrations were measured at 1-min intervals and plasma for propofol analyses was sampled every 20 min. To eliminate the influence of dosing on volatile propofol concentration, exhalation rate was normalized to plasma concentration.Results
In-vitro ventilation of double-lumen tubes resulted in increasing propofol concentrations at the distal end of the tube over time. In vitro clamping the bronchial lumen led to an even more pronounced increase (Δ AUC +62%) in propofol gas concentration over time. Normalized propofol exhalation during lung surgery was 31% higher during single-lung compared to double-lung ventilation.Conclusion
During single-lung ventilation, propofol concentration in exhaled air, in contrast to our expectations, increased by approximately one third. However, this observation might not be affected by change in perfusion-ventilation during single-lung ventilation but rather arises from reduced propofol absorption on the inner surface area of the double-lumen tube. Thus, it is only possible to utilize exhaled propofol concentration to a limited extent during single-lung ventilation.Registration of Clinical Trial
DRKS-ID DRKS00014788 ( www.drks.de ). 相似文献7.
Hendrik Kröning Thomas Göhler Thomas Decker Marc Grundeis Georgi Kojouharoff Jörg Lipke Dieter Semsek Enno Moorahrend Annette Sauer Harald-Robert Bruch Rüdiger Liersch Arnd Nusch Ursula Vehling-Kaiser Manfred Welslau Ralf Grunewald Hanns-Detlev Harich Marcel Stephany Jens Uhlig Rebecca de Buhr Melanie Frank Cathrin Hogrefe Norbert Marschner Karin Potthoff Frank Hartmann Timo Reisländer Ingo Schwaner 《International journal of cancer. Journal international du cancer》2023,153(6):1227-1240
The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression-free survival (PFS), safety, and quality of life (QoL). Subgroups comprised patients with good (<3 metastatic sites at inclusion, ≥18 months from diagnosis of first metastasis to inclusion) or poor (remaining patients) prognostic characteristics (GPC/PPC). GPC without liver metastases was considered best prognostic characteristics (BPC). In total, 307 eligible patients (pretreated or not suitable for other available therapies) were treated with FTD/TPI. Overall, median [95%-CI] OS was 7.4 months [6.4-8.6], median PFS was 2.9 months [2.8-3.3]. In BPC (n = 65) and GPC (n = 176) compared to PPC (n = 124) subgroup, median OS (13.3 [9.1-17.6] vs 8.9 [7.6-9.8] vs 5.1 [4.4-7.0] months) and median PFS (4.0 [3.3-5.3] vs 3.4 [3.0-3.7] vs 2.6 [2.4-2.8] months) were longer. Patient-reported QoL, assessed by validated questionnaires (EQ-5D-5L, PRO-CTCAE), was stable throughout FTD/TPI treatment. Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13.0%), leukopenia (7.5%), and anemia (5.2%). Altogether, palliative FTD/TPI therapy in patients with pretreated mCRC was associated with prolonged survival, delayed progression, maintained health-related QoL, and manageable toxicity. Low metastatic burden and indolent disease were favorable prognostic factors for survival. TACTIC confirms the effectiveness and safety of FTD/TPI, highlighting its value in routine clinical practice. 相似文献
8.
9.
Thomas Fuchs-Buder Sorin J. Brull Malin Jonsson Fagerlund J. Ross Renew Guy Cammu Glenn S. Murphy Michiel Warlé Matias Vested Béla Fülesdi Reka Nemes Malachy O. Columb Daniela Damian Peter J. Davis Hajime Iwasaki Lars I. Eriksson 《Acta anaesthesiologica Scandinavica》2023,67(8):994-1017
The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40 , 59–74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51 , 789–808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception. 相似文献
10.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献